Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories Limited held its 42nd Annual General Meeting on July 23, 2026 at 11:00 A.M. IST via Video Conferencing / Other Audio Visual Means in line with MCA and SEBI guidance. A quorum of 86 members holding 22,25,59,764 shares attended.
Shareholders approved adoption of the audited standalone and consolidated financial statements for the year ended March 31, 2026 and declared a final dividend of Rs. 8 per equity share of face value Re. 1 each. They re-appointed Mr. K Satish Reddy as director and appointed M/s. Deloitte Haskins & Sells LLP as statutory auditors for five consecutive years.
Special business included re-appointment of Dr. K P Krishnan as independent director for a second five-year term, appointment of Mr. Srikanth Velamakanni as independent director, and ratification of remuneration to cost auditors M/s Sagar & Associates for FY ending March 31, 2027. All resolutions were passed by requisite majority based on remote e-voting and e-voting during the AGM.
Dr. Reddy’s Laboratories Limited reported a change in auditors driven by mandatory auditor rotation under the Indian Companies Act, 2013. Deloitte Haskins & Sells LLP has been recommended as the new statutory auditor for 5 consecutive years, from the conclusion of the 42nd Annual General Meeting to the 47th, subject to shareholder approval. To align global reporting, the Board also approved Deloitte as the company’s Independent Registered Public Accounting Firm for its Form 20-F audits and Form 6-K interim reviews. Ernst & Young Associates LLP served in this role through the audit for the year ended March 31, 2026 and the interim review for the three months ended June 30, 2026. The company is using this report and EY’s accompanying letter to meet Item 16F(a) disclosure requirements and to incorporate the change into certain Form S-8 registration statements.
Dr. Reddy’s Laboratories Limited, a foreign private issuer, reports that audio recordings of its earnings call for the quarter ended June 30, 2026 are available online. The earnings call was conducted on July 22, 2026, and a web link has been provided to the listed stock exchanges for information and records.
Dr. Reddy’s Laboratories reported consolidated revenue of Rs.80,705 million for the three months ended June 30, 2026, down from Rs.85,452 million a year earlier. Profit for the period declined to Rs.4,348 million, with basic earnings per share of Rs.5.32 versus Rs.17.04.
Gross profit fell to Rs.37,540 million, as cost of revenues increased and inventory write-downs rose to Rs.3,451 million, including a Rs.2,397 million provision for out-of-specification Semaglutide batches. Operating profit dropped to Rs.3,784 million. Operating cash flow turned negative at Rs.(927) million, mainly reflecting working-capital movements.
Revenue from the United States decreased to Rs.22,659 million from Rs.36,544 million, while India, Russia and other markets grew. Total assets were Rs.575,305 million and total equity Rs.386,735 million as of June 30, 2026, with short-term borrowings of Rs.57,688 million and long-term lease liabilities of Rs.14,264 million.
Dr. Reddy’s Laboratories reported Q1 FY27 consolidated revenue of ₹80,705 Mn, down 6% year-on-year and up 7% sequentially. Gross margin was 46.5%, EBITDA was ₹10,088 Mn (12.5% margin), and profit after tax attributable to equity holders was ₹4,435 Mn, with diluted EPS of ₹5.32.
Performance was impacted by sharply lower lenalidomide revenues and a ₹2,397 Mn semaglutide API provision that reduced gross profit, EBITDA and PBT margins by about 3 percentage points; excluding this, gross, EBITDA and PBT margins were 49.4%, 15.4% and 9.8%, and annualised RoCE was 8%. PBT margin was 6.8% versus 22.3% a year earlier.
Revenue decline was concentrated in North America, while management highlighted double-digit base-business growth across key geographies. Emerging Markets revenue grew 31% YoY to ₹18,328 Mn and India grew 17% to ₹17,177 Mn; branded businesses contributed 52% of Q1 FY27 revenue. As of 30 June 2026, cash and other investments were ₹91,508 Mn, net cash surplus was ₹30,568 Mn and net debt/equity was -0.08 on equity of ₹386,735 Mn. The board appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and approved Deloitte Haskins & Sells LLP as independent registered public accounting firm for U.S. reporting.
Dr. Reddy’s Laboratories Limited reports that its board approved the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics, Senior Management Personnel and member of the Management Council, effective July 22, 2026. An updated list of the company’s Senior Management Personnel reflects this addition.
The board also approved the appointment of Deloitte Haskins & Sells LLP as the company’s Independent Registered Public Accounting Firm to audit financial statements included in the Annual Report on Form 20-F and review interim financial statements filed on Form 6-K. This aligns with an earlier decision to appoint Deloitte Haskins & Sells LLP as statutory auditors for a term of five consecutive years from the conclusion of the 42nd AGM to the conclusion of the 47th AGM, subject to shareholder approval.
Dr. Reddy’s Laboratories Limited approved a grant of 15,933 stock options to an eligible employee under the Dr. Reddy’s Employees Stock Option Scheme, 2018. The Nomination, Governance and Compensation Committee cleared the grant by circular resolution dated July 22, 2026.
The options are Indian Stock Options with an exercise price of Rs. 1,206 per share. They provide 100% vesting at the end of 3 years and are governed by the 2018 ESOP in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
Dr. Reddy’s Laboratories described a manufacturing issue in the scale‑up of the synthetic API for its semaglutide injection, where an impurity in finished product tested out of specification. The problem is confined to new scale‑up validation batches; material already supplied used a different scale, with no recalls or patient‑safety concerns identified.
Commercial supplies from the affected API facility are temporarily halted while the company investigates the root cause, adjusts the process and repeats three validation batches. Management currently expects this work, plus fill‑finish and sterility testing at partner OneSource, to run through late September, with API shipments in October and market supply resuming around late October or early November, subject to successful validation.
Because of the lost months, management now guides to 6–7 million pens of semaglutide injection in fiscal 2027, versus an earlier first‑year indication of 12 million pens. Semaglutide oral tablets, existing regulatory filings and cGMP compliance are unchanged, though batches linked to the issue at OneSource may require an inventory write‑down. The long‑term EBITDA margin goal of above 20% is reiterated.